Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26772791 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26772785 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2573660 | 0.95 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4125276 | 0.91 | SMN1; SMN2 (0.53) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24919476 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28924924 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28924921 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30273373 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28639757 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25005917 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023206665-A1 | PROCESS FOR UNPROTECTED ASYMMETRIC PREPARATION OF NICOTINE | 凯特立斯（深圳）科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| US-20230075688-A1 | PREPARATION METHOD OF RACEMIC NICOTINE | SHENZHEN ZINWI BIO-TECH CO., LTD (CN) | 2023-03-09 | — | — | US | disclosed |
| WO-2023004919-A1 | METHOD FOR PREPARING RACEMIC NICOTINE | 深圳市真味生物科技有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-20230025652-A1 | METHOD FOR PREPARING CHIRAL SYNTHETIC NICOTINE | SHENZHEN ZINWI BIO-TECH CO., LTD (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2023284058-A1 | METHOD FOR PREPARING CHIRAL SYNTHETIC NICOTINE | 深圳市真味生物科技有限公司 | 2023-01-19 | — | — | WO | disclosed |
| WO-2023284059-A1 | PREPARATION METHOD FOR SYNTHESIZING S-NICOTINE FROM GLUTARIC ACID ESTER | 深圳市真味生物科技有限公司 | 2023-01-19 | — | — | WO | disclosed |
| US-20210300889-A1 | METHOD FOR PREPARING ARTIFICIALLY SYNTHETIC (R,S)-NICOTINE SALT | FEELLIFE HEALTH INC. (CN) | 2021-09-30 | — | — | US | disclosed |
| US-10639300-B2 | Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists | SOLIS HERRERA ARTURO (MX) | 2020-05-05 | — | — | US | disclosed |
| US-20190111038-A1 | COMPOSITIONS AND METHODS FOR TREATING NASAL AND PARANASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | SOLIS HERRERA ARTURO (MX) | 2019-04-18 | — | — | US | disclosed |
| EP-3442583-A2 | COMPOSITIONS AND METHODS FOR TREATING PARANASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Solis Herrera, Arturo (MX) | 2019-02-20 | — | — | EP | disclosed |
| CN-102272246-B | Pyridine group-containing electrocoat resin | BASF COATINGS GMBH | 2014-09-17 | — | — | CN | disclosed |
| US-20140031554-A1 | PROCESS FOR PREPARING RACEMIC NICOTINE | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2014-01-30 | — | — | US | disclosed |
| US-20140031554-A1 | PROCESS FOR PREPARING RACEMIC NICOTINE | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2014-01-30 | — | — | US | disclosed |
| EP-2382274-A1 | PYRIDINE GROUP-CONTAINING ELECTROCOAT RESIN | BASF Coatings GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010077404-A1 | PYRIDINE GROUP-CONTAINING ELECTROCOAT RESIN | BASF COATINGS GMBH (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100167069-A1 | PYRIDINE GROUP-CONTAINING ELECTROCOAT RESIN | BASF CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100167071-A1 | PYRIDINE GROUP-CONTAINING ELECTROCOAT COMPOSITION WITH METAL OXIDE | BASF CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-6743939-B2 | NITRIC OXIDE SYNTHASE INHIBITORS; SUCH AS 4-CHLORO-2-(((1)-4-(METHYLAMINO)-1-PHENYLBUTYL)OXY)BENZONITRILE | ASTRAZENECA AB (SE) | 2004-06-01 | — | — | US | disclosed |
| EP-1263714-B1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030105161-A1 | Novel phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300889-A1 | METHOD FOR PREPARING ARTIFICIALLY SYNTHETIC (R,S)-NICOTINE SALT | SRM, BRSK2, BRSK1 | SMN1; SMN2 2550/4885CFTR 4268/4885SLC6A2 676/4885 |
| US-20230025652-A1 | METHOD FOR PREPARING CHIRAL SYNTHETIC NICOTINE | CHRNB1, CHRNB4, CHRNB3 | SMN1; SMN2 3075/4885CFTR 4844/4885SLC6A2 3847/4885 |
| US-20230075688-A1 | PREPARATION METHOD OF RACEMIC NICOTINE | NNMT, NAPRT, ADH1C | SMN1; SMN2 1719/4885CFTR 4480/4885SLC6A2 404/4885 |
| US-20140031554-A1 | PROCESS FOR PREPARING RACEMIC NICOTINE | NAPRT, NNMT, NAMPT | SMN1; SMN2 2492/4885CFTR 4581/4885SLC6A2 1033/4885 |
| US-20030105161-A1 | Novel phenylheteroalkylamine derivatives | NOS1, CYP1A1, NOS2 | SMN1; SMN2 2846/4885CFTR 1048/4885SLC6A2 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.